Optimizing Antiplatelet Therapy in the ACS Patient: The Intersection of Acute Coronary Syndromes and Oral Antiplatelet Therapy

This presentation aims to address the central role of platelets in acute coronary syndromes (ACS) and the use of both oral antiplatelet therapy and interventional therapy as cornerstones for the treatment of ACS. Topics to be discussed include the pharmacology of approved...

Optimizing Antiplatelet Therapy in the ACS Patient: Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel

This presentation focuses on the results of the TRITON-TIMI 38 trial, which examines the use of the investigational thienopyridine prasugrel compared to clopidogrel in patients with ACS who were undergoing primary PCI. Highlighted data from the trial is presented, including several in-depth...

Optimizing Antiplatelet Therapy in the ACS Patient: Limitations of Current Antiplatelet Therapy in ACS and PCI and Potential Solutions

This presentation aims to focus on current strategies to optimize oral antiplatelet agents in the treatment of ACS and PCI. Topics addressed include current limitations with clopidogrel, variability in response to clopidogrel and the clinical outcomes associated with poor response, and strategies...

Optimizing Antiplatelet Therapy in the ACS Patient: Panel Discussion

This presentation aims to address the central role of platelets in acute coronary syndromes (ACS) and the use of both oral antiplatelet therapy and interventional therapy as cornerstones for the treatment of ACS. Topics to be discussed include the pharmacology of approved and investigational oral...